Freespira named one of Fast Company's 2023 Most Innovative Companies.

Freespira in STAT: Read about Freespira's growth strategy here.

Debra Reisenthel

Debra Reisenthel

Board Member and Founding CEO

Debra is an experienced medical device and digital health CEO with a passion for breakthrough products and services that improve health, well-being and quality of life. She has broad operational and leadership roles in start-ups, corporate, and nonprofit organizations. Debra has a successful record of fundraising from venture capital, angel investors and non-profit donors, with significant expertise in working with government agencies, such as FDA and CMS in overcoming regulatory & reimbursement obstacles.

As Founding CEO of Freespira Inc., Debra grew the company from 2013-2018 by leading programs to expand Freespira’s evidence base with clinical trials for panic, PTSD and adolescents while driving a health economics study with a large payer. She also established relationships with leading payors and employers while managing the development and launch of the Freespira treatment for panic disorder, panic attacks and PTSD. Debra brings a unique blend of experience to Freespira, having successfully led early-stage ventures and leveraging her expertise in respiratory physiology.

Previous to Freespira, Debra worked with a Bay Area incubator (Exploramed) to develop a women’s health product. From 2001-2010, Debra was Founding President, CEO and Director at Novasys Medical where she led the development, launch and commercialization of the Renessa® treatment for female stress urinary incontinence.

Prior to Novasys, Debra was Vice President and General Manager at Tyco Inc. (Mallinckrodt, Nellcor Puritan Bennett, Nellcor), leading the development and commercialization of fetal oxygen monitoring. Early in her career Debra was Assistant Director of Respiratory Care at Loyola University Medical Center in Chicago, responsible for Labor & Delivery, Neonatal and Pediatrics.

Debra has held several Director positions in her career and is currently Director at Raydiant Oximetry, Inc., and Vice Chair of the Digital Therapeutics Alliance, the trade organization focused on broadening the understanding, adoption, and integration of clinically evaluated digital therapeutics with patients, clinicians, payors, and policymakers worldwide.

Debra holds a B.A. in Applied Behavioral Sciences, an MBA and R.R.T credentials.